
Hepatic Tumor - Pipeline Insight, 2025
Description
DelveInsight’s, “Hepatic Tumor - Pipeline Insight, 2025,”report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in Hepatic Tumor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Hepatic Tumor: Overview
Hepatic tumors, also known as liver tumors, encompass a broad spectrum of growths that can develop within the liver. These tumors can be benign or malignant and may originate from hepatocytes, the primary cell type in the liver, or from other cell types within the liver. The most common types of hepatic tumors include hepatocellular carcinoma (HCC), which arises from hepatocytes, and cholangiocarcinoma, which originates from the bile ducts within the liver. Other less common types include hepatic adenomas, focal nodular hyperplasia, and hemangiomas.
The causes of hepatic tumors are multifactorial and may include chronic liver diseases such as hepatitis B or C infection, alcoholic liver disease, non-alcoholic fatty liver disease (NAFLD), and certain genetic conditions. Environmental factors such as exposure to aflatoxins, a type of toxin produced by molds commonly found in grains and nuts, may also increase the risk of developing hepatic tumors. Additionally, lifestyle factors such as obesity, smoking, and excessive alcohol consumption are associated with an increased risk of liver cancer.
Symptoms of hepatic tumors can vary depending on the type of tumor and its size. Some common symptoms include abdominal pain or discomfort, unexplained weight loss, loss of appetite, nausea, jaundice (yellowing of the skin and eyes), and an enlarged liver. Diagnosis typically involves imaging studies such as ultrasound, CT scans, or MRI scans, as well as blood tests to assess liver function and tumor markers. Treatment options may include surgery, chemotherapy, radiation therapy, targeted therapy, and liver transplantation, depending on the type and stage of the tumor. Early detection and intervention are crucial for improving outcomes and prognosis in patients with hepatic tumors.
""Hepatic Tumor - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hepatic Tumor pipeline landscape is provided which includes the disease overview and Hepatic Tumor treatment guidelines. The assessment part of the report embraces, in depth Hepatic Tumor commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hepatic Tumor collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Hepatic Tumor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Hepatic Tumor Emerging Drugs
Further product details are provided in the report……..
Hepatic Tumor Therapeutic Assessment
This segment of the report provides insights about the different Hepatic Tumor drugs segregated based on following parameters that define the scope of the report, such as:
Hepatic Tumor: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III II, I, preclinical and discovery stage. It also analyses Hepatic Tumor therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hepatic Tumor drugs.
Hepatic Tumor Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Hepatic Tumor: Overview
Hepatic tumors, also known as liver tumors, encompass a broad spectrum of growths that can develop within the liver. These tumors can be benign or malignant and may originate from hepatocytes, the primary cell type in the liver, or from other cell types within the liver. The most common types of hepatic tumors include hepatocellular carcinoma (HCC), which arises from hepatocytes, and cholangiocarcinoma, which originates from the bile ducts within the liver. Other less common types include hepatic adenomas, focal nodular hyperplasia, and hemangiomas.
The causes of hepatic tumors are multifactorial and may include chronic liver diseases such as hepatitis B or C infection, alcoholic liver disease, non-alcoholic fatty liver disease (NAFLD), and certain genetic conditions. Environmental factors such as exposure to aflatoxins, a type of toxin produced by molds commonly found in grains and nuts, may also increase the risk of developing hepatic tumors. Additionally, lifestyle factors such as obesity, smoking, and excessive alcohol consumption are associated with an increased risk of liver cancer.
Symptoms of hepatic tumors can vary depending on the type of tumor and its size. Some common symptoms include abdominal pain or discomfort, unexplained weight loss, loss of appetite, nausea, jaundice (yellowing of the skin and eyes), and an enlarged liver. Diagnosis typically involves imaging studies such as ultrasound, CT scans, or MRI scans, as well as blood tests to assess liver function and tumor markers. Treatment options may include surgery, chemotherapy, radiation therapy, targeted therapy, and liver transplantation, depending on the type and stage of the tumor. Early detection and intervention are crucial for improving outcomes and prognosis in patients with hepatic tumors.
""Hepatic Tumor - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hepatic Tumor pipeline landscape is provided which includes the disease overview and Hepatic Tumor treatment guidelines. The assessment part of the report embraces, in depth Hepatic Tumor commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hepatic Tumor collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Hepatic Tumor R&D. The therapies under development are focused on novel approaches to treat/improve Hepatic Tumor.
This segment of the Hepatic Tumor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Hepatic Tumor Emerging Drugs
- Namodenoson: Can Fite Biopharma
- MTL CEBPA : MiNA Therapeutics
- Amivantamab: Janssen Research & Development, LLC
- Fostroxacitabine bralpamide: Medivir AB
- ETN101: Etnova Therapeutics Corp.
Further product details are provided in the report……..
Hepatic Tumor Therapeutic Assessment
This segment of the report provides insights about the different Hepatic Tumor drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Hepatic Tumor
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Hepatic Tumor: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III II, I, preclinical and discovery stage. It also analyses Hepatic Tumor therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hepatic Tumor drugs.
Hepatic Tumor Report Insights
- Hepatic Tumor Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Hepatic Tumor drugs?
- How many Hepatic Tumor drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hepatic Tumor?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Hepatic Tumor therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Hepatic Tumor and their status?
- What are the key designations that have been granted to the emerging drugs?
- Can Fite Biopharma
- MiNA Therapeutics
- Medivir AB
- Janssen Research & Development, LLC
- Etnova Therapeutics Corp.
- SillaJen Biotherapeutics
- Akeso Biopharma
- Shanghai Junshi Biosciences
- Genmab/Janssen Biotech
- Bio-Thera Solutions
- Ocuphire Pharma
- Surface Oncology
- Genoscience
- Onyx Pharmaceuticals
- Qurient Co., Ltd.
- Kowa Company, Ltd.
- Eureka Therapeutics Inc.
- Namodenoson
- MTL CEBPA
- Fostroxacitabine bralpamide
- Amivantamab
- ETN101
- Pexastimogene devacirepvec
- Cadonilimab
- Toripalimab
- Amivantamab
- Bevacizumab biosimilar
- APX3330
- SRF388
- GNS561
- PD-0332991
- Q702
- NIK-333
- ET14020
Table of Contents
240 Pages
- Introduction
- Executive Summary
- Hepatic Tumor : Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Late Stage Products (Phase III)
- Comparative Analysis
- Namodenoson: Can Fite Biopharma
- Product Description
- Research and Development
- Product Development Activities
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- MTL CEBPA : MiNA Therapeutics
- Product Description
- Research and Development
- Early Stage Products (Phase I)
- Comparative Analysis
- ETN101: Etnova Therapeutics Corp.
- Product Description
- Research and Development
- Product Development Activities
- Inactive Products
- Comparative Analysis
- Hepatic Tumor Key Companies
- Hepatic Tumor Key Products
- Hepatic Tumor - Unmet Needs
- Hepatic Tumor - Market Drivers and Barriers
- Hepatic Tumor - Future Perspectives and Conclusion
- Hepatic Tumor Analyst Views
- Hepatic Tumor Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.